ribosomal protein L10 pseudogene 19Genealiases: []
Q-omics provides the consensus-scored RPL10P19 profile across patient tissues and cancer cell-line models. RPL10P19 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, RPL10P19 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, RPL10P19 RNA expression shows 15,661 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, KIRC, and UVM as cancer lineages where RPL10P19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL10P19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL10P19 survival associations across molecular data types. RPL10P19 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL10P19 RNA expression–survival associations across cancer types. High RPL10P19 expression shows unfavorable associations in KIRC, but favorable associations in SKCM, BLCA, HNSC, LUAD and CESC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for RPL10P19 RNA expression.
This table summarizes RPL10P19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL10P19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL10P19 shows lower tumor expression in KIRC, KICH, LUAD, LUSC, BLCA and BRCA. The KIRC box plot shows higher RPL10P19 RNA expression in normal versus tumor tissue (log2 FC = −0.362, t-test p < 0.001).
This table shows molecular features associated with RPL10P19 in patient tissues and cancer cell lines. In patient samples, RPL10P19 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
